QuidelOrtho Corp
QDELNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for QDEL. That does not mean none is planned.
Get an email about QDEL's next catalysts
Track QuidelOrtho (QDEL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration (FDA) issued to Quidel the first emergency use authorization (EUA) for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.
WebsiteNo drugs found in this phase.
Frequently asked questions
When is QuidelOrtho Corp's next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for QuidelOrtho Corp (QDEL) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track QDEL biotech catalysts?β
Add QDEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow QuidelOrtho Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
